Beyond animal models, some studies have been performed on AD patients: Pierrot et al. [9] found that six months of 300 mg of daily Targretin treatment can increase memory in human AD patients by up to 40%, while also decreasing the concentration of tau in cerebrospinal fluid. Here, MAPT is linked to Alzheimer disease.